ASCO18: Updated Phase 1 results of crizotinib against MET-amplified lung cancer

(University of Colorado Anschutz Medical Campus) By lowering the bar for 'high MET amplification,' a study suggests that crizotinib may benefit more MET-amplified non-small cell lung cancer patients than previously thought.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news